# US 2023/0399319 A1 · Acylsulfamide Compound and Pharmaceutical Use Therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399319 A1
- Document ID: US20230399319A1
- Status: Published application
- Kind: A1
- Application number: 17/788,916
- Filed: 2020-12-25
- Published: 2023-12-14
- Earliest claimed: 2019-12-27
- Applicants: Japan Tobacco Inc.
- Inventors: Yusuke OHBA; Takayuki FURUKAWA; Kaoru ADACHI; Tatsuya NISHIMARU; Kentaro SAKURAI; Ritsuki MASUO; Tasuku INAMI
- Web page: https://patentgrep.com/patent/US20230399319A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 263/48: Nitrogen atoms not forming part of a nitro radical
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 413/14: containing three or more hetero rings
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/10: Spiro-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 487/08: Bridged systems
- C07D 491/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 498/08: Bridged systems
- C07D 498/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An acylsulfamide compound, or a pharmaceutically acceptable salt thereof, having NLRP3 inflammasome inhibitory activity, a pharmaceutical composition comprising the same, and their medical use, etc., are provided. A compound of Formula [Ia]: or a pharmaceutically acceptable salt thereof, wherein a partial structure: is: Ring Cy is an optionally substituted heteroaryl or phenyl; RDy and REy are each independently hydrogen, optionally substituted C1-6 alkyl, optionally substituted C1-4 haloalkyl, optionally substituted C3-6 cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl, or alternatively, RDy and REy may combine together with the nitrogen atom to which they attach to form heterocycloalkyl, etc.

## Claims

### Claim 1

A compound of Formula [Ia]:
or a pharmaceutically acceptable salt thereof, wherein
a partial structure:
is:
Ring Cy is 5- to 6-membered heteroaryl comprising 1 to 3 nitrogen atoms, or phenyl, wherein the heteroaryl or the phenyl is substituted with RF at one of the atoms of α-position to a Cy ring-constituting atom attached to the NH group directly attached to the partial structure, and may be optionally substituted with the same or different 1 to 4 RGs;
RDy and REy are each independently
(1) hydrogen,
(2) C1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 3 Rd1s,
(3) C1-4 haloalkyl,
(4) C3-6 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 to 3 halogen atoms,
(5) 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd2s, or
(6) 5- to 6-membered heteroaryl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaryl may be optionally substituted with C1-6 alkyl or C1-4 haloalkyl, or alternatively,
RDy and REy may combine together with the nitrogen atom to which they attach to form
(a) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs1ys and/or may be fused with a 5- to 6-membered heteroaromatic ring comprising 1 to 3 nitrogen atoms wherein the heteroaromatic ring may be optionally substituted with the same or different 1 or 2 Rd3s,
(b) 7- to 11-membered spiro heterocycloalkyl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the spiro heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd4s and/or may be optionally fused with a benzene ring,
(c) 6- to 10-membered fused heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the fused heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd4s, or
(d) 5- to 9-membered bridged heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the bridged heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd6s;
RF is
(1) halogen,
(2) C1-4 alkyl,
(3) C1-4 haloalkyl,
(4) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms, or
(5) C3-5 cycloalkyl,
RG is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-6 alkyl, wherein the alkyl may be optionally substituted with:
(a) C1-4 alkoxy,
(b) cyano,
(c) phenyl, or
(d) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms,
(3) C1-4 haloalkyl,
(4) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(5) cyano,
(6) CONRG1RG2, wherein RG1 and RG2 are each independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl,
(7) trialkylsilyl,
(8) pentafluorosulfanyl,
(9) C3-7 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 to 3 Rs2s,
(10) C5-13 spiro cycloalkyl, wherein the spiro cycloalkyl may be optionally substituted with the same or different 1 to 3 Rs3s,
(11) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs4s,
(12) 7- to 11-membered Spiro heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the spiro heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs5s,
(13) phenyl, wherein the phenyl may be optionally substituted with the same or different 1 to 3 Rs6s, and
(14) 5- to 6-membered heteroaryl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 Rs7s, or alternatively,
in the case where RF and RG or two RGs are substituted on neighboring atoms, then the RF and RG and/or the two RGs may combine together with the atoms to which they attach to form:
(a) a C5-6 cycloalkene ring, wherein the cycloalkene ring may be optionally substituted with the same or different 1 to 3 Rc1s,
(b) a 5- to 7-membered heterocycloalkene ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkene ring may be optionally substituted with the same or different 1 to 3 Rc2s,
(c) a benzene ring, wherein the benzene ring may be optionally substituted with the same or different 1 to 3 Rc3s, or
(d) a 5- to 7-membered heteroaromatic ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaromatic ring may be optionally substituted with the same or different 1 to 3 Rc4s,
so that Ring Cy may form a bi- or tri-cyclic fused ring group;
Rc1 Rc2, Rc3 and Rc4 are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-6 alkyl,
(3) C1-4 haloalkyl, and
(4) oxo;
Rd1 is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(4) cyano,
(5) COORe1, wherein Re1 is hydrogen or C1-6 alkyl,
(6) CONRe2Re3, wherein Re2 and Re3 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, or alternatively, Re2 and Re3 may combine together with the nitrogen atom to which they attach to form 5- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 or 2 halogen atoms,
(7) CORe4, wherein Re4 is C1-6 alkyl,
(8) SO2Re5, wherein Re5 is C1-6 alkyl,
(9) NRe6Re7, wherein Re6 is
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, and
Re7 is
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-4 haloalkyl,
(d) CORe8, wherein Re8 is C1-6 alkyl, and the alkyl may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(i) halogen,
(ii) hydroxy,
(iii) C1-6 alkoxy, and
(iv) cyano, or
(e) SO2Re9, wherein Re9 is C1-6 alkyl or C1-4 haloalkyl,
(10) SO2NRf1, Rf2, wherein Rf1 and Rf2 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl,
(11) C3-6 cycloalkyl, wherein the cycloalkyl may be optionally substituted with hydroxy or C1-6 alkoxy,
(12) 4- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of halogen and oxo,
(13) phenyl, and
(14) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heteroaryl may be optionally substituted with C1-6 alkyl or C1-4 haloalkyl;
Rd2 is each independently a substituent selected from the group consisting of:
(1) C1-6 alkyl,
(2) C1-4 haloalkyl,
(3) oxo, and
(4) CORg1, wherein Rg1 is C1-6 alkyl, and the alkyl may be optionally substituted with:
(a) hydroxy,
(b) C1-6 alkoxy, and
(c) cyano;
Rd3 is each independently a substituent selected from the group consisting of:
(1) C1-6 alkyl, and
(2) COORg2, wherein Rg2 is hydrogen or C1-6 alkyl;
Rd4, Rd5 and Rd6 are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) oxo,
(4) cyano,
(5) C1-6 alkyl,
(6) C1-4 haloalkyl,
(7) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(8) NRg3Rg4, wherein Rg3 and Rg4 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, and
(9) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with 1 or 2 substituents independently selected from the group consisting of:
(a) halogen,
(b) hydroxy,
(c) C1-6 alkyl,
(d) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms, and
(e) oxo;
Rs1y, Rs2, Rs3, Rs4, Rs5, Rs6, and Rs7 are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 3 R11ys,
(4) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(5) cyano,
(6) ORt1, wherein Rt1 is C3-6 cycloalkyl,
(7) COR12,
(8) SO2R13,
(9) NRt2Rt3, wherein Rt2 is
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, and
Rt3 is
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-4 haloalkyl,
(d) COR14, or
(e) SO2R15,
(10) CONRt4Rt5, wherein Rt4 and Rt5 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, or alternatively, Rt4 and Rt5 may combine together with the nitrogen atom to which they attach to form 4- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 or 2 halogen or hydroxy,
(11) SO2NRt6Rt7, wherein Rt6 and Rt7 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl,
(12) COORt8, wherein Rt8 is hydrogen or C1-6 alkyl,
(13) oxo,
(14) C3-6 cycloalkyl,
(15) phenyl,
(16) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 R16s, and
(17) 5- to 6-membered heteroaryl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 R17s;
R11y is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen,
(b) hydroxy,
(c) C1-6 alkoxy, and
(d) C3-6 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 to 3 R1dys,
(4) cyano,
(5) NR21R22, wherein R21 is
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, and
R22 is
(a) hydrogen,
(b) C1-6 alkyl,
(c) C1-4 haloalkyl,
(d) COR1a, or
(e) SO2R1b,
(6) COR23, wherein R23 is C1-6 alkyl or C1-4 haloalkyl,
(7) SO2R24y, wherein R24y is C1-6 alkyl, wherein the alkyl may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen, and
(b) C3-6 cycloalkyl,
(8) COOR25, wherein R25 is hydrogen or C1-6 alkyl,
(9) CONR26R27, wherein R26 and R27 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, or alternatively, R26 and R27 may combine together with the nitrogen atom to which they attach to form 5- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 or 2 halogen atoms,
(10) SO2NR28R29, wherein R28 and R29 are independently
(a) hydrogen,
(b) C1-6 alkyl, or
(c) C1-4 haloalkyl, or alternatively, R28 and R29 may combine together with the nitrogen atom to which they attach to form 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 or 2 halogen atoms,
(11) C3-6 cycloalkyl,
(12) 4- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 R1cs,
(13) phenyl,
(14) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 R1eys, and
(15) OR30y, wherein R30y is C3-6 cycloalkyl which may be optionally substituted with the same or different 1 to 3 R1fys;
R17 and R1ey are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-6 alkyl,
(3) C1-4 haloalkyl,
(4) C1-6 alkoxy,
(5) cyano,
(6) C3-6 cycloalkyl, and
(7) 4- to 6-membered heterocycloalkyl comprising an oxygen atom;
R12, R13, R14, R15, R1a, and R1b are each independently a substituent selected from the group consisting of:
(1) C1-6 alkyl,
(2) C1-4 haloalkyl,
(3) C3-6 cycloalkyl,
(4) 4- to 6-membered heterocycloalkyl comprising an oxygen atom,
(5) phenyl, and
(6) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms;
R16, R1c, R1dy, and R1fy are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkyl,
(4) C1-4 haloalkyl,
(5) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms, and
(6) oxo.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
RDy and REy are each independently
(1) hydrogen,
(2) C1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 3 Rd1s,
(3) C3-6 cycloalkyl,
(4) 4- to 7-membered heterocycloalkyl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, or
(5) 5- to 6-membered heteroaryl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaryl may be optionally substituted with C1-4 alkyl,
or alternatively,
RDy and REy may combine together with the nitrogen atom to which they attach to form
(a) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs1ys and/or may be fused with a 5- to 6-membered heteroaromatic ring comprising 1 to 3 nitrogen atoms wherein the heteroaromatic ring may be optionally substituted with the same or different 1 or 2 Rd3s,
(b) 7- to 11-membered spiro heterocycloalkyl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the spiro heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd4s,
(c) 6- to 10-membered fused heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, or
(d) 5- to 9-membered bridged heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms,
RF is
(1) halogen,
(2) C1-4 alkyl,
(3) C1-4 haloalkyl,
(4) C1-4 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms, or
(5) C3-5 cycloalkyl,
RG is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-6 alkyl, wherein the alkyl may be optionally substituted with:
(a) C1-4 alkoxy, or
(b) cyano,
(3) C1-4 haloalkyl,
(4) C1-4 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(5) cyano,
(6) pentafluorosulfanyl, and
(7) C3-7 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 or 2 Rs2s, or alternatively,
in the case where RF and RG or two RGs are substituted on neighboring atoms, then the RF and RG and/or the two RGs may combine together with the atoms to which they attach to form:
(a) a C5-6 cycloalkene ring,
(b) a 5- to 7-membered heterocycloalkene ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkene ring may be optionally substituted with the same or different 1 or 2 Rc2s, or
(c) a 5- to 7-membered heteroaromatic ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms,
so that Ring Cy may form a bi- or tri-cyclic fused ring group,
Rc2 is each independently C1-4 alkyl,
Rd1 is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-4 alkoxy,
(3) cyano,
(4) CONRe2Re3, wherein Re2 and Re3 are independently
(a) hydrogen, or
(b) C1-4 alkyl,
(5) SO2Re5, wherein Re5 is C1-4 alkyl,
(6) NRe6Re7 wherein Re6 is
(a) hydrogen, or
(b) C1-4 alkyl, and
Re7 is
(a) hydrogen,
(b) C1-4 alkyl, or
(c) CORe8, wherein Re8 is C1-4 alkyl,
(7) C3-6 cycloalkyl,
(8) phenyl, and
(9) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heteroaryl may be optionally substituted with C1-4 alkyl,
Rd3 is each independently a substituent selected from the group consisting of:
(1) C1-4 alkyl, and
(2) COORg2, wherein Rg2 is hydrogen or C1-4 alkyl;
Rd4 is each independently a substituent selected from the group consisting of:
(1) oxo, and
(2) C1-4 alkyl,
Rs1y and Rs2 are each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 3 R11ys,
(4) C1-6 alkoxy,
(5) cyano,
(6) COR12,
(7) SO2R13,
(8) NRt2Rt3, wherein Rt2 is
(a) hydrogen, or
(b) C1-6 alkyl, and
Rt3 is
(a) hydrogen,
(b) C1-6 alkyl,
(c) COR14, or
(d) SO2R15,
(9) CONRt4Rt5, wherein Rt4 and Rt5 are independently
(a) hydrogen, or
(b) C1-6 alkyl, or alternatively, Rt4 and Rt5 may combine together with the nitrogen atom to which they attach to form 4- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms,
(10) SO2NRt6Rt7, wherein Rt6 and Rt7 are independently
(a) hydrogen, or
(b) C1-6 alkyl,
(11) COORt8, wherein Rt8 is hydrogen or C1-4 alkyl,
(12) oxo,
(13) phenyl, and
(14) 5- to 6-membered heteroaryl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 R17s;
R11y is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen,
(b) hydroxy,
(c) C1-4 alkoxy, and
(d) C3-6 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 to 3 R1dys,
(4) cyano,
(5) NR21R22 wherein R21 and R22 are each independently
(a) hydrogen, or
(b) C1-4 alkyl,
(6) SO2R24y, wherein R24y is C1-6 alkyl, wherein the alkyl may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen, and
(b) C3-6 cycloalkyl,
(7) 4- to 6-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 R1cs, and
(8) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 R1eys;
R17 and R1ey are each independently a substituent selected from the group consisting of:
(1) C1-6 alkyl,
(2) C1-4 haloalkyl, and
(3) C1-6 alkoxy;
R12, R13, R14, and R15 are each independently a substituent selected from the group consisting of:
(1) C1-6 alkyl,
(2) C1-4 haloalkyl,
(3) C3-6 cycloalkyl, and
(4) 4- to 6-membered heterocycloalkyl comprising an oxygen atom;
R1dy is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy, and
(3) C1-4 alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
RF is
(1) methyl, ethyl, isopropyl, or tert-butyl,
(2) C1-4 haloalkyl,
(3) C1-4 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms, or
(4) C3-5 cycloalkyl,
RG is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) C1-6 alkyl, wherein the alkyl may be optionally substituted with:
(a) C1-4 alkoxy, or
(b) cyano,
(3) C1-4 haloalkyl,
(4) C1-4 alkoxy, wherein the alkoxy may be optionally substituted with the same or different 1 to 3 halogen atoms,
(5) cyano,
(6) pentafluorosulfanyl, and
(7) C3-7 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 or 2 Rs2s, or alternatively,
in the case where RF and RG or two RGs are substituted on neighboring atoms, then the RF and RG and/or the two RGs may combine together with the atoms to which they attach to form:
(a) a C5-6 cycloalkene ring,
(b) a 5- to 7-membered heterocycloalkene ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heterocycloalkene ring may be optionally substituted with the same or different 1 or 2 Rc2s, or
(c) a 5- to 7-membered heteroaromatic ring comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms,
so that Ring Cy may form a bi- or tri-cyclic fused ring group;
Rs2 is each independently a substituent selected from the group consisting of:
(1) C1-4 alkyl, and
(2) cyano;
R11y is each independently a substituent selected from the group consisting of:
(1) halogen,
(2) hydroxy,
(3) C1-6 alkoxy, wherein the alkoxy may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen,
(b) hydroxy,
(c) C1-4 alkoxy, and
(d) C3-6 cycloalkyl, wherein the cycloalkyl may be optionally substituted with the same or different 1 to 3 R1dys,
(4) cyano,
(5) NR21R22, wherein R22 and R22 are each independently
(a) hydrogen, or
(b) C1-4 alkyl,
(6) SO2R24y, wherein R24y is C1-6 alkyl, wherein the alkyl may be optionally substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) halogen, and
(b) C3-6 cycloalkyl, and
(7) 5- to 6-membered heteroaryl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the heteroaryl may be optionally substituted with the same or different 1 to 3 R1eys.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
a partial structure:
is a group of the following formula:

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
RDy and REy combine together with the nitrogen atom to which they attach to form
(1) 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs1ys and/or may be fused with a 5- to 6-membered heteroaromatic ring comprising 1 to 3 nitrogen atoms wherein the heteroaromatic ring may be optionally substituted with the same or different 1 or 2 Rd3s,
(2) 7- to 11-membered spiro heterocycloalkyl comprising 1 to 3 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, wherein the spiro heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rd4s,
(3) 6- to 10-membered fused heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms, or
(4) 5- to 9-membered bridged heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen and oxygen atoms.

### Claim 6 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
RDy and REy combine together with the nitrogen atom to which they attach to form 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl may be optionally substituted with the same or different 1 to 3 Rs1ys and/or may be fused with a 5- to 6-membered heteroaromatic ring comprising 1 to 3 nitrogen atoms wherein the heteroaromatic ring may be optionally substituted with the same or different 1 or 2 Rd3s.

### Claim 7 (depends on 1)

The compound according to claim 1, having a structure of the following formula [II]:
or a pharmaceutically acceptable salt thereof,
wherein
Ring Cy2y is 4- to 7-membered heterocycloalkyl comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur atoms, wherein the heterocycloalkyl comprises at least one nitrogen atom and may be optionally substituted with the same or different 1 to 3 Rs1ys,
Rs1y, Ring Cy, and the partial structure comprising A and B are those as defined in claim 1.

### Claim 8 (depends on 1)

The compound according to claim 1, having a structure of the following formula [III]:
or a pharmaceutically acceptable salt thereof,
wherein
n1 is an integer from 0 to 3,
Rs1y, Ring Cy, and the partial structure comprising A and B are those as defined in claim 1.

### Claim 9 (depends on 1)

The compound according to claim 1, having a structure of the following formula [IV]:
or a pharmaceutically acceptable salt thereof,
wherein
n2 is an integer from 0 to 2,
Rs1y, Ring Cy, and the partial structure comprising A and B are those as defined in claim 1.

### Claim 10 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Cy is the following formula:
wherein
n3 is an integer from 0 to 4,
RF and RG are those as defined in claim 1.

### Claim 11 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Cy is the following formula:
wherein
n4 is an integer from 0 to 3,
RF and RG are those as defined in claim 1.

### Claim 12 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ring Cy is the following formula:
wherein
n5 is an integer of 0 or 1,
RF and RG are those as defined in claim 1.

### Claim 13 (depends on 1)

The compound according to claim 1, selected from:
and
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

An NLRP3 inflammasome inhibitor comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method for inhibiting NLRP3 inflammasome, comprising administering a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, to a mammal.

### Claim 19 (depends on 1)

A method for treating or preventing a disease selected from the group consisting of multiple sclerosis, chronic kidney disease and inflammatory bowel disease, comprising administering a therapeutically effective amount of a compound according to of claim 1, or a pharmaceutically acceptable salt thereof, to a mammal.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.

### Claim at position 21

21-26. (canceled)